Small molecule inhibitors of the ribosome biogenesis factor NVL2

Abstract

Described are dibenzothiazepinone and dibenzazepinone-based compounds, methods for treating cancers with small molecule inhibitors of the ribosome biogenesis factor NVL2, related pharmaceutical compositions, methods to inhibit ribosome biogenesis or induce p53 or inhibit cancer cells and methods …